S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61

Biocept Stock Forecast, Price & News

-0.06 (-6.40%)
(As of 06/24/2022 06:55 PM ET)
Today's Range
50-Day Range
52-Week Range
275,700 shs
Average Volume
126,929 shs
Market Capitalization
$15.23 million
P/E Ratio
Dividend Yield
Price Target
30 days | 90 days | 365 days | Advanced Chart

Receive BIOC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biocept and its competitors with MarketBeat's FREE daily newsletter.

BIOC Stock Forecast (MarketRank)

Overall MarketRank

1.68 out of 5 stars

Medical Sector

915th out of 1,411 stocks

Medical Laboratories Industry

22nd out of 31 stocks

Analyst Opinion: 3.5Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
Biocept logo

About Biocept (NASDAQ:BIOC)

Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians; clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations; and RT-PCR testing services for COVID-19. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California.

BIOC Stock News Headlines

Biocept, Inc. (NASDAQ:BIOC) Short Interest Update
Form 8-K BIOCEPT INC For: Jun 10 - StreetInsider.com
Biocept (NASDAQ:BIOC) Now Covered by StockNews.com
See More Headlines

Industry, Sector and Symbol

Medical laboratories
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
2 Analysts


Net Income
$-2.82 million
Pretax Margin


Sales & Book Value

Annual Sales
$61.25 million
Book Value
$2.23 per share


Free Float
Market Cap
$15.23 million

Biocept Frequently Asked Questions

Should I buy or sell Biocept stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biocept in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Biocept stock.
View analyst ratings for Biocept
or view top-rated stocks.

What is Biocept's stock price forecast for 2022?

2 Wall Street research analysts have issued 12-month target prices for Biocept's stock. Their BIOC stock forecasts range from $4.00 to $4.00. On average, they predict Biocept's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 344.4% from the stock's current price.
View analysts' price targets for Biocept
or view top-rated stocks among Wall Street analysts.

How has Biocept's stock performed in 2022?

Biocept's stock was trading at $3.62 at the beginning of 2022. Since then, BIOC stock has decreased by 75.1% and is now trading at $0.90.
View the best growth stocks for 2022 here

Are investors shorting Biocept?

Biocept saw a drop in short interest in May. As of May 31st, there was short interest totaling 243,600 shares, a drop of 16.2% from the May 15th total of 290,700 shares. Based on an average daily trading volume, of 103,900 shares, the short-interest ratio is presently 2.3 days.
View Biocept's Short Interest

When is Biocept's next earnings date?

Biocept is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022.
View our earnings forecast for Biocept

How were Biocept's earnings last quarter?

Biocept, Inc. (NASDAQ:BIOC) posted its quarterly earnings data on Monday, May, 23rd. The medical research company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.14) by $0.02. The medical research company had revenue of $19.95 million for the quarter, compared to analysts' expectations of $6.99 million. Biocept had a negative net margin of 11.26% and a negative trailing twelve-month return on equity of 19.99%.
View Biocept's earnings history

When did Biocept's stock split? How did Biocept's stock split work?

Biocept shares reverse split on Tuesday, September 8th 2020. The 1-10 reverse split was announced on Friday, September 4th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Friday, September 4th 2020. An investor that had 100 shares of Biocept stock prior to the reverse split would have 10 shares after the split.

Who are Biocept's key executives?

Biocept's management team includes the following people:
  • Mr. Samuel D. Riccitelli, Interim Pres, CEO & Chairman (Age 63, Pay $67.24k)
  • Mr. Antonino Morales, Interim CFO & Director (Age 66, Pay $20.76k)
  • Dr. Michael C. Dugan M.D., Sr. VP, Chief Medical Officer & Medical Director (Age 59, Pay $413.31k)
  • Dr. Soon Kap Hahn Ph.D., Founder
  • Dr. Philippe J. Marchand Ph.D., Chief Operating Officer (Age 59)
  • Mr. Pavel Tsinberg, Director of Technology Devel.
  • Mr. Darrell Taylor Esq., Sr. VP, Chief Legal Officer & Chief Compliance Officer (Age 57)
  • Mr. David S. Moskowitz R.Ph., MBA, VP of Strategy & Corp. Communications
  • Mr. Michael Terry, Sr. VP of Corp. Devel. (Age 67)
  • Antonio Paternostro, VP of Sales

What is Michael Nall's approval rating as Biocept's CEO?

1 employees have rated Biocept CEO Michael Nall on Glassdoor.com. Michael Nall has an approval rating of 100% among Biocept's employees. This puts Michael Nall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Biocept own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biocept investors own include T2 Biosystems (TTOO), iBio (IBIO), VBI Vaccines (VBIV), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Onconova Therapeutics (ONTX), Walmart (WMT), Inovio Pharmaceuticals (INO) and Acasti Pharma (ACST).

What is Biocept's stock symbol?

Biocept trades on the NASDAQ under the ticker symbol "BIOC."

Who are Biocept's major shareholders?

Biocept's stock is owned by a variety of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (0.69%), Acadian Asset Management LLC (0.16%), Taylor & Morgan Wealth Management LLC (0.14%), Group One Trading L.P. (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Company insiders that own Biocept stock include David F Hale and David F Hale.
View institutional ownership trends for Biocept

Which institutional investors are selling Biocept stock?

BIOC stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC.
View insider buying and selling activity for Biocept
or view top insider-selling stocks.

Which institutional investors are buying Biocept stock?

BIOC stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Taylor & Morgan Wealth Management LLC, and Group One Trading L.P..
View insider buying and selling activity for Biocept
or or view top insider-buying stocks.

How do I buy shares of Biocept?

Shares of BIOC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biocept's stock price today?

One share of BIOC stock can currently be purchased for approximately $0.90.

How much money does Biocept make?

Biocept (NASDAQ:BIOC) has a market capitalization of $15.23 million and generates $61.25 million in revenue each year. The medical research company earns $-2.82 million in net income (profit) each year or ($0.45) on an earnings per share basis.

How many employees does Biocept have?

Biocept employs 104 workers across the globe.

How can I contact Biocept?

Biocept's mailing address is 5810 Nancy Ridge Drive, San Diego CA, 92121. The official website for Biocept is www.biocept.com. The medical research company can be reached via phone at (858) 320-8200, via email at [email protected], or via fax at 858-320-8225.

This page (NASDAQ:BIOC) was last updated on 6/27/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.